342 related articles for article (PubMed ID: 27563824)
1. Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.
Nagpal P; Akl MR; Ayoub NM; Tomiyama T; Cousins T; Tai B; Carroll N; Nyrenda T; Bhattacharyya P; Harris MB; Goy A; Pecora A; Suh KS
Oncotarget; 2016 Oct; 7(41):67551-67573. PubMed ID: 27563824
[TBL] [Abstract][Full Text] [Related]
2. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
3. Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances.
Munir F; Hardit V; Sheikh IN; AlQahtani S; He J; Cuglievan B; Hosing C; Tewari P; Khazal S
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373245
[TBL] [Abstract][Full Text] [Related]
4. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
5. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
[TBL] [Abstract][Full Text] [Related]
8. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
9. Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.
Eichenauer DA; Engert A
Eur J Haematol; 2014 Jul; 93(1):1-8. PubMed ID: 24750367
[TBL] [Abstract][Full Text] [Related]
10. Novel agents for the treatment of Hodgkin lymphoma.
Dumaswala K; Mehta A
Expert Rev Hematol; 2015 Oct; 8(5):659-67. PubMed ID: 26343891
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan.
Tien FM; Tsai CH; Liu JH; Lin CT
J Formos Med Assoc; 2019 Oct; 118(10):1466-1470. PubMed ID: 31337522
[TBL] [Abstract][Full Text] [Related]
12. Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.
Metzger ML; Link MP; Billett AL; Flerlage J; Lucas JT; Mandrell BN; Ehrhardt MJ; Bhakta N; Yock TI; Friedmann AM; de Alarcon P; Luna-Fineman S; Larsen E; Kaste SC; Shulkin B; Lu Z; Li C; Hiniker SM; Donaldson SS; Hudson MM; Krasin MJ
J Clin Oncol; 2021 Jul; 39(20):2276-2283. PubMed ID: 33826362
[TBL] [Abstract][Full Text] [Related]
13. Current approaches to the management of pediatric Hodgkin lymphoma.
Freed J; Kelly KM
Paediatr Drugs; 2010 Apr; 12(2):85-98. PubMed ID: 20218745
[TBL] [Abstract][Full Text] [Related]
14. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
[TBL] [Abstract][Full Text] [Related]
15. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.
Nagpal P; Descalzi-Montoya DB; Lodhi N
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1311. PubMed ID: 33103852
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapeutic Management of Pediatric Lymphoma.
Mauz-Körholz C; Ströter N; Baumann J; Botzen A; Körholz K; Körholz D
Paediatr Drugs; 2018 Feb; 20(1):43-57. PubMed ID: 29127674
[TBL] [Abstract][Full Text] [Related]
17. Novel Therapies in the Treatment of Hodgkin Lymphoma.
Andrade-Gonzalez X; Ansell SM
Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
Gandolfi L; Pellegrini C; Casadei B; Stefoni V; Broccoli A; Tonialini L; Morigi A; Argnani L; Zinzani PL
Oncologist; 2016 Dec; 21(12):1436-1441. PubMed ID: 27486201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
